Healthcare Private Placement and M&A Transactions Review Week Ending January 1 2023

NextPoint: The company raised $80 million of venture funding from undisclosed investors on December 19, 2022. The company is a developer of medications intended to expand the benefit of immunotherapies to cancer patients.

Apnimed: The company raised $79.8 million of Series C3 venture funding from undisclosed investors on December 23, 2022, putting the company’s pre-money valuation at $280.3 million. The company is a developer of a pharmacologic therapy designed to target, with simple orally dosed medicines, the key underlying neurobiological mechanisms that lead to airway obstruction.

Rakuten Medical: The company raised $75.2 million of venture funding in the form of convertible notes from undisclosed investors December 28, 2022. The company is a developer of precision-targeted cancer therapies designed to treat solid tumors.

Vaxess Technologies: The company raised $35 million of Series B venture funding from Global Health Investment Fund and other undisclosed investors on December 23, 2022. The company is a developer of novel therapies designed to help in oncology care and infectious diseases.

Precision Neuroscience: The company raised $34.3 million of Series B venture funding from undisclosed investors on December 19, 2022, putting the company’s pre-money valuation at $100 million. The company is a developer of a neural platform for next-generation brain-computer interface technology, with a focus on minimally invasive device delivery.

Aliada Therapeutics: The company raised $33 million of seed funding from Johnson & Johnson Innovation – JJDC, RA Capital Management and other undisclosed investors on July 6, 2021. The company is a developer of novel therapies intended to treat central nervous system diseases.

Ribon Therapeutics: The company raised an additional $25 million of Series B1 venture funding from undisclosed investors on December 22, 2022, putting the company’s pre-money valuation at $210 million. The company is a developer of a biopharmaceutical platform designed to block a cancer cell’s fundamental ability to survive under stress.

Protillion Biosciences: The company raised $18 million in Series A venture funding in a deal led by ARCH Venture Partners and Illumina Ventures on December 19, 2022, putting the company’s pre-money valuation at $19.5 million. The company is focused on accelerating the selection of novel protein-based drug candidates while improving their potential for success in the clinical setting.

Cardurion Pharma: The company raised $17.5 million of venture funding from undisclosed investors on December 30, 2022. The company is a developer of cardiovascular therapeutics intended to treat cardiovascular diseases.

Novoron: The company raised $12.1 million of venture funding from undisclosed investors on December 19, 2022. The company develops novel therapeutics to address neurodegenerative disorders.

Seneca Therapeutics: The company raised $7.7 million of venture funding on December 22, 2022. from Mid Atlantic Bio Angels, Keiretsu Forum, VisionTech Partners and Thylacine Capital. The company is a developer of complex targeted biologics intended to offer cancer therapeutics, cancer vaccines and vaccines for infectious diseases.

TeraImmune: The company raised $3.0 million of venture funding in form of convertible debt from undisclosed investors on December 22, 2022. The company is a developer of cell therapeutics intended to treat autoimmune diseases and immune-related disorders.

Disc Medicine / Gemini Therapeutics: The company acquired Gemini Therapeutics through a reverse merger for $175 million, resulting in the combined entity trading on the NASDAQ stock exchange under the ticker symbol IRON on December 30, 2022. The company develops drugs to assist in the treatment of hematologic diseases.

IsoPlexis / Berkeley Lights: The company reached a definitive agreement to be acquired by Berkeley Lights for $57.8 million on December 21, 2022. IsoPlexis Corp is a developer of a single-cell detection system designed to accelerate insights in the field of cancer.

ArcherDX / Integrated DNA Technologies: The company was acquired by Integrated DNA Technologies, a subsidiary of Danaher, for an estimated $48 million on December 20, 2022. The company is a developer of next-generation sequencing-based gene fusion detection assays intended to target enrichment chemistry.

Abiomed / Johnson & Johnson: The company was acquired by Johnson & Johnson for approximately $16.6 billion on December 22, 2022. Abiomed Inc provides temporary mechanical circulatory support devices that are primarily used by interventional cardiologists and heart surgeons.

Bunzl Healthcare / Mediq: The company, a subsidiary of Bunzl reached a definitive agreement to be acquired by Mediq, via its financial sponsor Advent International, on December 20, 2022 for an undisclosed amount. The company is a provider of medical services intended to serve private healthcare service providers, medical suppliers and the National Health Service.

Discngine / Chemical Computing Group: The company was acquired by Chemical Computing Group, via its financial sponsor Altaris Capital Partners, through an LBO on December 22, 2022 for an undisclosed amount. The company is a developer of software and applications for life-science researchers.

Swellbox / Datavant: The company was acquired by Datavant, via its financial sponsors The Goldman Sachs Group, Mubadala Investment Company, Flex Capital, Cigna Ventures, Johnson & Johnson Innovation – JJDC, Sixth Street Partners and Transformation Capital, through an LBO on December 20, 2022 for an undisclosed amount. The company is a developer of a digital health record platform intended to offer lifetime health accounts.